SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia’s CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025.
Dr. Altman will share recent business developments on the Company’s therapeutic development pipeline with a focus on its lead CardiAMP autologous cell therapy for the treatment of ischemic heart failure.
Fireside Chat Details:
Date: Wednesday, May 21, 2025
Time: 03:40 p.m. EDT
Speaker: Peter Altman Ph.D., CEO
Moderator: Jim Molloy, AGP Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals
Webcast: https://us02web.zoom.us/webinar/register/WN_jB1HgKLvQFmUfC6VBT11mw
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit www.biocardia.com.
CONTACT: MEDIA CONTACT: Miranda Peto, Investor Relations mpeto@biocardia.com (650) 226-0120 INVESTOR CONTACT: David McClung, Chief Financial Officer investors@biocardia.com (650) 226-0120

| Nov-12 | |
| Nov-12 | |
| Nov-10 | |
| Nov-09 | |
| Nov-06 | |
| Oct-19 | |
| Oct-07 | |
| Oct-01 | |
| Sep-23 | |
| Sep-10 | |
| Aug-24 | |
| Aug-13 | |
| Aug-12 | |
| Aug-05 | |
| Jun-18 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite